Back to Cell Types

DELHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 10 publications

Quick Overview

DEL is a human T-cell line derived from malignant histiocytosis, characterized by CD30 positivity and a t(5;6)(q35;p21) translo...

Detailed Summary

The DEL cell line was established from a pleural effusion of a 12-year-old boy with malignant histiocytosis. It exhibits strong positivity for CD25, CD34, CD54, KIM7, and HLA class I and II antigens. The cell line shows a rearrangement of the immunoglobulin heavy chain gene (JH) and a trans-line configuration of the T-chain gene. It also has a translocation between chromosomes 5 and 6 with a breakpoint at q35. DEL is used to study the role of the c-fms oncogene and mononuclear phagocyte growth factors in malignant histiocytosis. The cell line is valuable for research on the molecular mechanisms of this disease and for developing targeted therapies.

Research Applications

Study of malignant histiocytosisInvestigation of c-fms oncogene and mononuclear phagocyte growth factorsDevelopment of targeted therapies

Key Characteristics

CD30 positivityt(5;6)(q35;p21) translocationRearrangement of immunoglobulin heavy chain gene (JH)Trans-line configuration of T-chain gene

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1170
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	12
Age Category	Pediatric
Sex	Male

Disease Information

Disease	ALK-positive anaplastic large cell lymphoma
Lineage	Lymphoid
Subtype	Anaplastic Large-Cell Lymphoma ALK Positive
OncoTree Code	ALCLALKP

DepMap Information

Source Type	DSMZ
Source ID	ACH-000233_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ser215Cys (c.643A>T)	Homozygous	-	Unknown
MutationSimple	RAC1	p.Ala88Glu (c.263C>A)	Heterozygous	-	Unknown
Gene fusion	ALK	NPM1-ALK	-	-	PubMed=9121481, PubMed=7824924

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

11,12

D13S317

11,12

D16S539

11,13

D18S51

12,18

D19S433

14,16

D21S11

28,31

D2S1338

17,21

D3S1358

15

D5S818

9,13

D7S820

9,11

D8S1179

12,13

FGA

19,22

Penta D

9,10

Penta E

12

TH01

6,9

TPOX

8

vWA

16,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.

Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Langerak A.W.

Leukemia 21:230-237(2007).

Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma.

Drexler H.G., MacLeod R.A.F.

Leukemia 18:1569-1571(2004).

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Quentmeier H., Drexler H.G.

Leukemia 10:142-149(1996).

DEL cell line: a 'malignant histiocytosis' CD30+ t(5;6)(q35;p21) cell line.

Richard S., Soulie J., Nezelof C.

Int. J. Cancer 45:546-553(1990).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

Web Resources